Last update :
03/05/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Anticancer drug   Doxorubicin hydrochloride  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Adriacept Germany
Adriamycin Australia, Austria, Canada, Denmark, Finland, Norway, United States of America
Adriblastin Austria, Switzerland
Adriblastina Belgium, Brazil, Croatia, Greece, Italy, Poland, Slovenia, Turkey
Adriblastine France, Greece
Adrimedac Germany
Biorub Brazil
Biorubina Poland
Dicladox Argentina
Doxolem Brazil
Doxorubicine France, Switzerland
Doxorubin Belgium, Greece
Farmiblastina Spain
Rastocin Poland
Robodoxo Germany
Stability of mixtures   Injection   Stability of mixtures : Doxorubicin hydrochloride     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Glass Sodium chloride 0,9% 0,1 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Granisetron hydrochloride 0,5 mg/ml
20°C-23°C
2 Hour
Protect from light 57
Level of evidence A+
Glass Glucose 5% 0,1 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Palonosetron hydrochloride 25 µg/ml
23°C
4 Hour
Not specified 1955
Level of evidence A+
Polyvinyl chloride Water for Injection 2 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,2 mg/ml
37°C
7 Day
Protect from light 1408
Level of evidence A+
Polyvinyl chloride Water for Injection 2 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,2 mg/ml
8°C
14 Day
Protect from light 1408
Level of evidence A+
Polyvinyl chloride Sodium chloride 0,9% 0,8 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Ondansetron hydrochloride 0,96 mg/ml
Injection   Vincristine sulfate 0,028 mg/ml
30°C
5 Day
Not specified 26
Level of evidence D
Polyvinyl chloride Sodium chloride 0,9% 1,67 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,036 mg/ml
35°C
4 Day
Protect from light 32
Level of evidence A+
Polyvinyl chloride Sodium chloride 0,9% 1,67 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,036 mg/ml
4°C
7 Day
Protect from light 32
Level of evidence A+
Polyvinyl chloride Glucose 5% 0,1 & 2 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Ondansetron hydrochloride 0,03 & 0,3 mg/ml
21°C-23°C
48 Hour
Light 184
Level of evidence C+
Polyvinyl chloride Glucose 5% 0,8 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Ondansetron hydrochloride 0,64 mg/ml
Injection   Dacarbazine 8 mg/ml
30°C
24 Hour
Not specified 26
Level of evidence D
Polyvinyl chloride Glucose 5% 0,8 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Ondansetron hydrochloride 0,64 mg/ml
Injection   Dacarbazine 8 mg/ml
4°C
7 Day
Protect from light 26
Level of evidence D
Polyolefine NaCl 0,9% or Glucose 5% 0,2 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Paclitaxel 0,3 & 1,2 mg/ml
23°C
24 Hour
Light 1286
Joker
Polyolefine NaCl 0,9% or Glucose 5% 0,2 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Paclitaxel 0,3 & 1,2 mg/ml
32°C
24 Hour
Light 1286
Joker
Polyolefine NaCl 0,9% or Glucose 5% 0,2 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Paclitaxel 0,3 & 1,2 mg/ml
4°C
24 Hour
Protect from light 1286
Joker
Polyolefine Sodium chloride 0,9% 0,12 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Etoposide phosphate 0,6 mg/ml
Injection   Vincristine sulfate 0,005 mg/ml
2-6°C
5 Day
Protect from light 1606
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,24 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Etoposide phosphate 1,2 mg/ml
Injection   Vincristine sulfate 0,010 mg/ml
2-6°C
5 Day
Protect from light 1606
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,4 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Etoposide phosphate 2 mg/ml
Injection   Vincristine sulfate 0,016 mg/ml
2-6°C
5 Day
With or without light 1606
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,050 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,002 mg/ml
Injection   Etoposide 0,250 mg/ml
23°C-25°C
72 Hour
With or without light 1033
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,025 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,001 mg/ml
Injection   Etoposide 0,125 mg/ml
23°C-25°C
96 Hour
With or without light 1033
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,035 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,0014 mg/ml
Injection   Etoposide 0,175 mg/ml
23°C-25°C
96 Hour
With or without light 1033
Level of evidence A
Polyolefine Sodium chloride 0,9% 1,4 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,033 & 0,053 mg/ml
25°C
4 Day
Not specified 2094
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,040 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,0016 mg/ml
Injection   Etoposide 0,200 mg/ml
31°C-33°C
72 Hour
With or without light 1033
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,12 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Etoposide phosphate 0,6 mg/ml
Injection   Vincristine sulfate 0,005 mg/ml
35°C-40°C
5 Day
Protect from light 1606
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,24 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Etoposide phosphate 1,2 mg/ml
Injection   Vincristine sulfate 0,010 mg/ml
35°C-40°C
5 Day
Protect from light 1606
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,4 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Etoposide phosphate 2 mg/ml
Injection   Vincristine sulfate 0,016 mg/ml
35°C-40°C
5 Day
With or without light 1606
Level of evidence A
Polyolefine Sodium chloride 0,9% 1,4 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,033 & 0,053 mg/ml
8°C
14 Day
Not specified 2094
Level of evidence A
Polysiloxane Sodium chloride 0,9% 1,4 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,033 mg/ml
25°C
14 Day
Protect from light 408
Level of evidence C
Polysiloxane Sodium chloride 0,9% 1,4 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,033 mg/ml
37°C
7 Day
Protect from light 408
Level of evidence C
Polysiloxane NaCl 0,45% Glucose 2,5% 1,4 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,033 mg/ml
25°C
14 Day
Protect from light 408
Level of evidence C
Polysiloxane NaCl 0,45% Glucose 2,5% 1,4 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,033 mg/ml
37°C
7 Day
Protect from light 408
Level of evidence C
Polyisoprene elastomer Sodium chloride 0,9% 0,12 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,005 mg/ml
Injection   Etoposide phosphate 0,6 mg/ml
2-6°C
14 Day
Not specified 4102
Level of evidence A+
Polyisoprene elastomer Sodium chloride 0,9% 0,24 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,01 mg/ml
Injection   Etoposide phosphate 1,2 mg/ml
2-6°C
14 Day
Not specified 4102
Level of evidence A+
Polyisoprene elastomer Sodium chloride 0,9% 0,4 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,016 mg/ml
Injection   Etoposide phosphate 2 mg/ml
2-6°C
14 Day
Not specified 4102
Level of evidence A+
Polyisoprene elastomer Sodium chloride 0,9% 0,12 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,005 mg/ml
Injection   Etoposide phosphate 0,6 mg/ml
35°C
7 Day
Protect from light 4102
Level of evidence A+
Polyisoprene elastomer Sodium chloride 0,9% 0,24 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,01 mg/ml
Injection   Etoposide phosphate 1,2 mg/ml
35°C
7 Day
Protect from light 4102
Level of evidence A+
Polyisoprene elastomer Sodium chloride 0,9% 0,4 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Vincristine sulfate 0,016 mg/ml
Injection   Etoposide phosphate 2 mg/ml
35°C
7 Day
Protect from light 4102
Level of evidence A+
Not specified NaCl 0,9% or Glucose 5% 1 mg/ml
Injection   Doxorubicin hydrochloride   
Injection   Topotecan 0,028 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
  Mentions Légales